Cosmos Health's Liv18 Liver Supplement Commences Sales, Projects $5M+ Annual Revenue at 75% Gross Margins
COSM sits 35% above its 52-week low of $0.28.
Summary
Cosmos Health announced the successful completion of Phase 1 execution for its Liv18 liver health supplement, with production and sales commencing in April 2026. This update provides concrete progress on the U.S. launch, which was initially announced as planned for Q2 2026 on April 8th. The company projects Liv18 to generate over $5 million in annual revenue at approximately 75% gross margins, a highly significant financial contribution relative to Cosmos Health's current market valuation. This accelerated commercialization and strong revenue/margin projection indicate a material uplift to the company's U.S. expansion and overall profitability. Investors will closely monitor initial sales performance and the realization of these financial targets.
At the time of this announcement, COSM was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2M. The 52-week trading range was $0.28 to $1.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Access Newswire.